| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Urea J Acid does not have a pharmacological target. It is an industrial chemical used primarily as an intermediate in dye and pigment production. Its mechanism of action is not relevant to biological systems, as it is not intended for therapeutic use. It may interact with biological systems as a chemical irritant, but this is not a pharmacological effect.
|
|---|---|
| ln Vitro |
AMI-1 free acid has been shown to inhibit the in vitro methylation processes of all five recombinantly active PRMTs (PRMT1, -3, -4, and -6, as well as Hmt1p)[2]. AMI-1 free acid inhibits both type I PRMTs (PRMT1, 3, 4, and 6) and type II PRMT5 [2]. In vitro, AMI-1 free acid inhibits arginine methyltransferase activity but not lysine, and it does not compete with AdoMet for the binding site[3]. Free acid prevents the methylation of GFP-Npl3 and cellular proteins[3]. AMI-1 free acid (0.6-2.4 mM; 48-96 hours) reduces sarcoma cell survival in S180 and U2OS cells in a time- and dose-dependent manner in vitro[4]. AMI-1 free acid (1.2-2.4 mM; 48-72 hours) lowers S180 cell viability by inducing cell death [4].
Urea J Acid is not used in pharmacological activity assays. Its properties are evaluated in the context of dye and pigment chemistry. Its reactivity and ability to form dyes are characterized using chemical and physical methods. It is not used in standard pharmacological in vitro assays. |
| ln Vivo |
S180 viability is inhibited in vivo by AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days)[4]. In a tumor xenograft model, AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not control PRMT7 expression[4]. In a tumor xenograft model, AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) reduces the levels of H4R3me2s and H3R8me2s[4].
Urea J Acid is not used as a drug and does not have in vivo pharmacological activity. Its effects are observed in industrial applications where it is used as an intermediate for dye production. It is not administered to animals or humans for therapeutic purposes. |
| Enzyme Assay |
As an industrial chemical, Urea J Acid does not have a typical enzyme/receptor binding assay. Its properties are assessed based on its chemical and physical characteristics, such as purity, solubility, and reactivity. It is not used in standard pharmacological binding assays.
|
| Cell Assay |
Cell Viability Assay[4]
Cell Types: S180 cells, U2OS cells Tested Concentrations: 0.6mM, 1.2mM, 2.4mM Incubation Duration: 48 hrs (hours), 72 hrs (hours), 96 hrs (hours) Experimental Results: Inhibited the cell viability. Apoptosis Analysis[4] Cell Types: S180 cells Tested Concentrations: 1.2mM, 2.4mM Incubation Duration: 48 hrs (hours), 72 hrs (hours) Experimental Results: Increased the percentages of cells undergoing apoptosis. Urea J Acid is not typically used in cell-based assays. Its applications are primarily in the dye and pigment industries. The compound's effects on cells are not a primary focus of study, as it is not intended for biological or therapeutic use. Its safety in biological systems may be assessed for regulatory purposes. |
| Animal Protocol |
Animal/Disease Models: 6- 7 weeks old male Kunming mice (18-22 g), with S180 cells xenograft[4]
Doses: 0.5 mg Route of Administration: Intratumorally, daily, for 7 days Experimental Results: diminished tumor weight. Urea J Acid is not used in animal experiments for pharmacological purposes. Its effects are studied in the context of industrial applications. Animal studies may be conducted for toxicological evaluation to assess its safety for occupational exposure or environmental impact, but these are not typical pharmacological studies. |
| ADME/Pharmacokinetics |
Urea J Acid has a molecular weight of 269.28 and a molecular formula of C11H11N3O4S. It is a solid that is typically used as an intermediate in chemical synthesis. Its physical properties, such as melting point and solubility, are characterized for its use in dye and pigment production.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Urea J Acid has been evaluated for occupational exposure. It may cause skin and eye irritation upon contact. Inhalation of dust may cause respiratory irritation. The compound is not intended for human consumption, and appropriate safety measures should be taken when handling it in an industrial setting.
|
| References |
|
| Additional Infomation |
Urea J Acid is a chemical intermediate used in the production of dyes, pigments, and optical brighteners. It is a derivative of J acid and urea. The compound is not a pharmaceutical agent and is not intended for human therapeutic use. It is available from various chemical suppliers for industrial and research purposes.
|
| Molecular Formula |
C21H16N2O9S2
|
|---|---|
| Molecular Weight |
504.4897
|
| Exact Mass |
504.03
|
| CAS # |
134-47-4
|
| Related CAS # |
AMI-1;20324-87-2
|
| PubChem CID |
67254
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.798 g/cm3
|
| Melting Point |
86-88 °C
|
| Index of Refraction |
-45 ° (C=1, AcOH)
|
| LogP |
5.849
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
886
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PCGISRHGYLRXSR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H16N2O9S2/c24-19-9-15(33(27,28)29)7-11-5-13(1-3-17(11)19)22-21(26)23-14-2-4-18-12(6-14)8-16(10-20(18)25)34(30,31)32/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32)
|
| Chemical Name |
4-hydroxy-7-[(5-hydroxy-7-sulfonaphthalen-2-yl)carbamoylamino]naphthalene-2-sulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~165.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9822 mL | 9.9110 mL | 19.8220 mL | |
| 5 mM | 0.3964 mL | 1.9822 mL | 3.9644 mL | |
| 10 mM | 0.1982 mL | 0.9911 mL | 1.9822 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
